APS:TSX-Aptose Biosciences Inc (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 1.34

Change

0.00 (0.00)%

Market Cap

CAD 0.12B

Volume

3.93K

Avg Analyst Target

CAD 9.00 (+571.64%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Aptose Biosciences Inc (APS) Stock Analysis:
Based on the Aptose Biosciences Inc stock forecasts from 3 analysts, the average analyst target price for Aptose Biosciences Inc is CAD 9.00 over the next 12 months. Aptose Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aptose Biosciences Inc is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Aptose Biosciences Inc’s stock price was CAD 1.34. Aptose Biosciences Inc’s stock price has changed by +2.29% over the past week, -11.84% over the past month and -78.46% over the last year.

About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatmen ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TRIL:CA Trillium Therapeutics Inc

N/A

CAD2.43B 1.80 N/A
BLU:CA BELLUS Health Inc

-0.45 (-3.98%)

CAD1.21B N/A N/A
LMNL:CA Liminal BioSciences Inc

N/A

CAD0.54B 1.28 N/A
FRX:CA Fennec Pharmaceuticals Inc

+0.22 (+3.06%)

CAD0.19B 30.20 N/A
IMV:CA IMV Inc

+0.08 (+6.30%)

CAD0.10B -99,999.99 N/A
BCT:CA BriaCell Therapeutics Corp.

+0.26 (+4.18%)

CAD0.09B N/A N/A
ONC:CA Oncolytics Biotech Inc

-0.01 (-0.70%)

CAD0.08B N/A N/A
MDNA:CA Medicenna Therapeutics Corp

-0.03 (-2.24%)

CAD0.08B 5.40 N/A
RVX:CA Resverlogix Corp

+0.01 (+3.45%)

CAD0.07B 27.50 26.37
IGX:CA Intelgenx Technologs

-0.03 (-5.88%)

CAD0.07B N/A N/A

ETFs Containing APS:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.54% 69% D+ 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.54% 69% D+ 16% F
Trailing 12 Months  
Capital Gain -79.19% 24% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.19% 24% F 1% F
Trailing 5 Years  
Capital Gain -6.29% 71% C- 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.29% 71% C- 26% F
Average Annual (5 Year Horizon)  
Capital Gain 41.21% 82% B- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.21% 82% B- 93% A
Risk Return Profile  
Volatility (Standard Deviation) 114.57% 24% F 5% F
Risk Adjusted Return 35.97% 76% C 44% F
Market Capitalization 0.12B 88% B+ 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.26 93% A 58% F
Price / Cash Flow Ratio -2.85 35% F 81% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -69.39% 73% C 8% F
Return on Invested Capital -67.77% 59% F 5% F
Return on Assets -40.40% 59% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 22.13 12% F 4% F
Short Percent 0.90% 13% F 63% D
Beta 1.24 50% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector